首页> 美国卫生研究院文献>Journal of Hematology Oncology >Safety pharmacokinetics and antitumor properties of anlotinib an oral multi-target tyrosine kinase inhibitor in patients with advanced refractory solid tumors

【2h】

Safety pharmacokinetics and antitumor properties of anlotinib an oral multi-target tyrosine kinase inhibitor in patients with advanced refractory solid tumors

机译：口服多靶酪氨酸激酶抑制剂anlotinib在晚期难治性实体瘤患者中的安全性药代动力学和抗肿瘤特性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundAnlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotinib in patients with advanced refractory solid tumors.

机译：背景技术Anlotinib是一种新型的多靶酪氨酸激酶抑制剂，旨在主要抑制VEGFR2 / 3，FGFR1-4，PDGFRα/β，c-Kit和Ret。我们旨在评估晚期难治性实体瘤患者中安洛替尼的安全性，药代动力学和抗肿瘤活性。

著录项

期刊名称 Journal of Hematology Oncology
作者
Yongkun Sun; Wei Niu; Feng Du; Chunxia Du; Shuting Li; Jinwan Wang; Li Li; Fengqing Wang; Yu Hao; Chuan Li; Yihebali Chi;
展开▼
作者单位

展开▼
年(卷),期 2016(9),-1
年度 2016
页码 105
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;血液学检验;
关键词
Anlotinib Anti-angiogenesis Phase I study Advanced refractory solid tumors Pharmacokinetics Safety;

机译：安洛替尼;抗血管生成;I期研究;晚期难治性实体瘤;药代动力学;安全性;

相似文献

外文文献
中文文献
专利

1. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors [J] . Nishina Tomohiro, Takahashi Shunji, Iwasawa Ryota, Investigational new drugs. . 2018,第3期

机译：Erdafitinib的安全性，药代动力学和药效学，一种先进或难治性固体瘤患者的泛成纤维细胞生长因子受体（FGFR）酪氨酸激酶抑制剂
2. Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors [J] . SoriaJ.-C., CortesJ., MassardC., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第2期

机译：口服pan-HER受体酪氨酸激酶抑制剂BMS-599626（AC480）在患有晚期实体瘤的患者中的第一阶段安全性，药代动力学和药效学试验
3. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. [J] . Okamoto I, Kaneda H, Satoh T, Molecular cancer therapeutics . 2010,第10期

机译：口服三重酪氨酸激酶抑制剂BIBF 1120在晚期实体瘤患者中的I期安全性，药代动力学和生物标志物研究。
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. First-in-human open-label dose-escalation and dose-expansion study of the safety pharmacokinetics and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors [O] . Tianhong Li, Patricia LoRusso, Michael L. Maitland, 2016

机译：口服ALK抑制剂ASP3026在晚期实体瘤患者中的安全性药代动力学和抗肿瘤作用的首次人类公开标签剂量递增和剂量扩展研究
7. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors [O] . Yongkun Sun, Wei Niu, Feng Du, 2016

机译：口服多靶酪氨酸激酶抑制剂anlotinib在晚期难治性实体瘤患者中的安全性，药代动力学和抗肿瘤特性

Safety pharmacokinetics and antitumor properties of anlotinib an oral multi-target tyrosine kinase inhibitor in patients with advanced refractory solid tumors

摘要

著录项

相似文献

相关主题

期刊订阅